Research programme: sodium channel blockers - RaQualia PharmaAlternative Names: RQ-00203066
Latest Information Update: 27 Jul 2016
At a glance
- Originator Pfizer
- Developer RaQualia Pharma
- Class Amides
- Mechanism of Action Nav1.3 voltage-gated sodium channel inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Inflammatory pain; Neuropathic pain